Animal models of arthritis suggest alpha-MSH peptides can reduce joint inflammation, but that has not been confirmed in human trials
Execution discipline becomes the limiter
9 Todays SYNCHRONIZE-1 topline results strengthen our confidence in survodutide as a treatment candidate capable of addressing obesity and potentially offering targeted weight loss to help address connected conditions including liver disease, said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim
Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S
Inscrivez-vous notre newsletter Obtenez toutes les dernires informations sur les vnements, les ventes et les offres
2011 Aug;94(8):4016-27